---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-26-000005"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:13:41.911786+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech KB407 Phase 1 positive: CFTR delivery confirmed in all 6 biopsied patients

## Summary
- Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations (modulator ineligible).
- Transduction rates ranged 29.4% to 42.1% across six patients; all biopsies positive for CFTR or viral marker.
- KB407 well tolerated; one SAE (asthma exacerbation) deemed procedure-related, resolved in 5 days.
- Registrational CORAL-3 study design submitted to FDA; enrollment expected 1H 2026 after alignment.
- Four of seven highest-dose patients were modulator ineligible; data supports mutation-agnostic potential.

## SEC filing metadata
- accession: 0001711279-26-000005
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127926000005/0001711279-26-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127926000005/krys-20260108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-26-000005
- JSON: https://secwatch.observer/filing/0001711279-26-000005.json
- Plain text: https://secwatch.observer/filing/0001711279-26-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.